Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: pain

Trump Panel Urges More Treatment Options to Fight Opioid Crisis

Toni Clarke  |  

(Reuters)—A panel convened by U.S. President Donald Trump to tackle the opioid crisis called on Wednesday for more treatment programs, tighter prescribing guidelines and additional drug courts to help reduce overdose deaths. The commission, led by New Jersey Governor Chris Christie, said the recommendations would require funding by Congress but did not recommend an amount….

New Jersey Sues OxyContin Maker, Links Marketing to Opioid Crisis

Jonathan Stempel  |  

(Reuters)—New Jersey on Tuesday sued Purdue Pharma LP, accusing the OxyContin maker of contributing to the state’s opioid crisis through deceptive marketing to doctors and patients, including the elderly and the “opioid-naive.” Christopher Porrino, the New Jersey attorney general, faulted what he called a decade-long marketing campaign of “almost inconceivable callousness and irresponsibility, and said…

Varus Thrust Is Associated with Progressive Knee OA

  |  

To determine if varus thrust, a bowing out of the knee during gait (i.e., the first appearance or worsening of varus alignment during stance), is associated with incident and progressive knee osteoarthritis (OA), these researchers undertook an Osteoarthritis Initiative ancillary study. They also considered hypothesized associations adjusted for static alignment, anticipating some attenuation. Methods: Gait…

Billionaire Insys Founder Charged in U.S. Opioid Bribe Case

Nate Raymond  |  

BOSTON (Reuters)—The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic. John Kapoor, Insys’ majority shareholder who stepped down as chief executive in January, was charged…

Trump Declares Opioids a U.S. Public Health Emergency

Yasmeen Abutaleb and Jeff Mason  |  

WASHINGTON (Reuters)—U.S. President Donald Trump declared the opioid crisis a public health emergency on Thursday, stopping short of a national emergency declaration he promised months ago that would have freed up more federal money. Responding to a growing problem wreaking havoc in rural areas, Trump’s declaration will redirect federal resources and loosen regulations to combat…

FDA Sets Stricter Requirements for Immediate-Release Opioids to Prevent Misuse & Abuse

  |  

The FDA is expanding its Risk Evaluation and Mitigation Strategy (REMS) to include manufacturers of immediate-release opioids. The makers of these drugs will soon be required to provide training and education to healthcare professionals on the proper prescription and use of the drugs for pain management…

U.S. to Promote Use of Opioid Alternatives to Treat Addiction

Toni Clarke  |  

(Reuters)—The U.S. Food and Drug Administration plans to encourage opioid addicts to use less harmful opioid drugs such as methadone and buprenorphine, a radical shift in policy that could agitate those in the addiction field who believe abstinence is the only effective treatment. Speaking before the House Committee on Energy and Commerce on Wednesday, FDA…

Rhode Island Doctor Pleads Guilty to Opioid Kickback Scheme

Nate Raymond  |  

BOSTON (Reuters)—A Rhode Island doctor pleaded guilty on Wednesday to charges he participated in a scheme to obtain kickbacks in exchange for writing prescriptions for an addictive fentanyl-based cancer pain drug produced by Insys Therapeutics Inc. The plea by Jerrold Rosenberg came amid ongoing investigations of Insys related to Subsys, an under-the-tongue spray that contains…

GSK Wins U.S. Shingles Vaccine Approval, U.K. Nod for Gene Therapy

Ben Hirschler  |  

LONDON (Reuters)—GlaxoSmithKline has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year. It also secured a recommendation from U.K. cost authorities for a $700,000 gene therapy for so-called “bubble boy” disease—a step forward for the field of fixing faulty…